天人平喘胶囊治疗慢性阻塞性肺病 (肺肾气虚型)随机双盲对照研究

何江; 常智玲; 管慧; 周棉勇; 李世红; 廖沙; 阳淑芳

您当前的位置：

首页 >

文章列表页 >

天人平喘胶囊治疗慢性阻塞性肺病 (肺肾气虚型)随机双盲对照研究

更新时间：2024-01-04

- 天人平喘胶囊治疗慢性阻塞性肺病 (肺肾气虚型)随机双盲对照研究
- Randomized Double-blind Controlled Study on Tianren Pingchuan Capsules in Treatment of Chronic Obstructive Pulmonary Disease (Deficiency of Pulmonary and Renal Vital Energy)
- 中国实验方剂学杂志 2012年18卷第14期页码：250-253
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家中医药管理局课题(国中医2007010号)
- DOI：
  中图分类号：
- 纸质出版日期：2012
- 稿件说明：
移动端阅览
何江, 常智玲, 管慧, 等. 天人平喘胶囊治疗慢性阻塞性肺病 (肺肾气虚型)随机双盲对照研究[J]. 中国实验方剂学杂志, 2012,18(14):250-253.

HE Jiang, CHANG Zhi-ling, GUAN Hui, et al. Randomized Double-blind Controlled Study on Tianren Pingchuan Capsules in Treatment of Chronic Obstructive Pulmonary Disease (Deficiency of Pulmonary and Renal Vital Energy)[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(14): 250-253.
何江, 常智玲, 管慧, 等. 天人平喘胶囊治疗慢性阻塞性肺病 (肺肾气虚型)随机双盲对照研究[J]. 中国实验方剂学杂志, 2012,18(14):250-253. DOI：

HE Jiang, CHANG Zhi-ling, GUAN Hui, et al. Randomized Double-blind Controlled Study on Tianren Pingchuan Capsules in Treatment of Chronic Obstructive Pulmonary Disease (Deficiency of Pulmonary and Renal Vital Energy)[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(14): 250-253. DOI：

摘要

目的: 观察天人平喘胶囊治疗慢性阻塞性肺病(肺肾气虚型)的疗效和安全性。方法: 采用随机双盲安慰剂对照试验设计方法

选择120例慢性阻塞性肺病患者

随机分为治疗组和对照组

每组60例

两组均采用最佳西医治疗方案

治疗组并在此基础上分别加口服天人平喘胶囊

对照加服安慰剂胶囊。两组服药方法为每日3次

每次3粒

每日总剂量450 mg。治疗疗程均为24周。观察中医证候、生活质量评分(SGRQ评分)、运动耐量(6MWT)、肺功能以及再次急性加重的例次及安全性指标。结果: 治疗组和对照总有效率分别为89.28%和60.34%

差异有统计学意义(P<0.01);两组治疗后咳嗽、咯痰、气促、胸闷评分及总分与治疗前比较均降低(P<0.01);治疗组积分改变优于对照(P<0.05);治疗24周后

治疗组SGRQ评分较治疗前明显降低

而6MWT距离则明显提高 (P<0.01);治疗组SGRQ 评分及6MWT距离改善明显优于对照(P<0.05)。治疗组和对照病例再次发生急性加重的例次发生率分别为5.36%(3/56) 和20.68%(12/58)

差异有统计学意义 (P<0.05)。结论: 天人平喘胶囊能改善慢性阻塞性肺病(肺肾气虚型)通气功能

具有明显疗效和良好的安全性。

Abstract

Objective: To observe the curative effect and safety of Tianren Pingchuan capsule in treatment of chronic obstructive pulmonary disease (deficiency of pulmonary and renal vital energy). Method: A design of randomized

placebo-controlled

double-blind trial was adopted. The 120 cases of chronic obstructive pulmonary disease were selected and randomly divided into treatment group and control group

with 60 cases in each group respectively. The best western medical therapy solution was applied to both groups

on which basis Tianren Pingchuan capsules and placebo capsules was used respectively. Three times a day

3 capsules each time and total daily dose of 450 mg.The course of treatment was 24 weeks. Tranditional Chinese medicine (TCM) syndromes

st. George vespiratory questimnaire scores(SGRQ)

6 minute walk test(6MWT)

pulmonary function

cases and safety index of acute re-exacerbation were observed. Result: Curative effect of TCM syndromes: the total efficacious rate in treatment group and control group was 89.28% and 60.34% respectively

with statically significant differences (P<0.01)

improvement of TCM syndromes: In both groups

the scores and total scores for cough

expectoration

anhelation and chest distress after treatment were lower than those before treatment (P<0.01); score changes in treatment group were superior to that in control group (P<0.05). Life quality and exercise tolerance: after 24-week treatment

SGRQ score in treatment group obviously decreased with remarkable improvement of 6MWT distances (P<0.01); SGRQ score in treatment group and 6MWT distances were better than those in control group (P<0.05). Cases of acute re-exacerbation: the incidence of acute re-exacerbation in treatment group and control group was 5.36% (3/56) and 20.68% (12/58) respectively

with statically significant differences (P<0.05). Conclusion: Tianren Pingchuan capsules can improve ventilation function for chronic obstructive pulmonary disease (deficiency of pulmonary and renal vital energy)

with remarkable efficacy and satisfactory safety.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

“脾-肠-肌”的中医模式探讨肠道微生态延缓COPD肌少症的新机制

基于“肺与大肠相表里”探讨中医药调控肠道菌群治疗慢性阻塞性肺疾病的内涵

泽漆水提物对香烟烟雾诱导小鼠慢性阻塞性肺病及肺组织癌前病变相关蛋白的影响